Farxiga Tablet, Film Coated
Product Images NDC 50090-3482

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 13 technical images submitted to the FDA as part of the official labeling for Farxiga (NDC 50090-3482). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Figure 4 (Figure 4)

Figure 4 (Figure 4)
A line graph comparing the percentage of patients with an event over 60 months from randomization between FARXIGA and placebo. The y-axis represents patients with event (%) and the x-axis shows months from randomization. FARXIGA has a consistently lower percentage of patients with events compared to placebo. Patient counts at risk are listed below the graph for both FARXIGA and placebo at multiple time points.*
FDA Label Image

Figure 5 (Figure 5)

Figure 5 (Figure 5)
A Kaplan-Meier curve showing the percentage of patients with event over 60 months from randomization, comparing FARXIGA (dapagliflozin) and placebo. The graph shows fewer events over time in the FARXIGA group than placebo, with patient counts at risk indicated at intervals below the x-axis.*
FDA Label Image

Figure 6a (Figure 6a)

Figure 6a (Figure 6a)
A Kaplan-Meier curve chart comparing patients with events (%) over 24 months from randomization for FARXIGA (dapagliflozin) and placebo groups. The chart plots the cumulative incidence of events, showing lower event rates for FARXIGA versus placebo. Below the graph, the number of patients at risk is listed over time for both groups. The figure includes hazard ratio (HR) with confidence interval (CI) and P-value data for FARXIGA vs placebo.*
FDA Label Image

Figure 6b (Figure 6b)

Figure 6b (Figure 6b)
A Kaplan-Meier curve comparing the percentage of patients with events over 24 months between FARXIGA and placebo groups. The y-axis shows percentage of patients with events, and the x-axis represents months from randomization. FARXIGA has a lower event rate compared to placebo. The chart includes a hazard ratio with confidence interval and p-value, and the number of patients at risk is displayed below the x-axis for both groups at multiple time points.*
FDA Label Image

Figure 6c (Figure 6c)

Figure 6c (Figure 6c)
A Kaplan-Meier curve comparing the percentage of patients with an event over 24 months from randomization in a FARXIGA vs. placebo study. The graph indicates the cumulative event rates, with FARXIGA showing a lower event percentage than placebo. Patient counts at risk at various time points up to 24 months for both groups are displayed below the x-axis.*
FDA Label Image

Figure 7 (Figure 7)

Figure 7 (Figure 7)
A forest plot comparing the composite primary endpoint outcomes between FARXIGA and placebo groups across various patient characteristics such as age, sex, race, geographic region, NYHA class, LVEF, NT-proBNP, prior hospitalization for heart failure, MRA use, diabetes status, atrial fibrillation, heart failure etiology, BMI, and baseline eGFR. The plot uses hazard ratios (HR) and 95% confidence intervals to show the relative effect of FARXIGA versus placebo.*
FDA Label Image

Dapagliflozin Chemical Structure (Dapagliflozin Struct)

Dapagliflozin Chemical Structure (Dapagliflozin Struct)
Chemical structure of dapagliflozin, the active ingredient in FARXIGA tablets, shown as a molecular diagram including its sugar moiety and substituents.*
FDA Label Image

Figure 1 (Farxiga Fig1)

Figure 1 (Farxiga Fig1)
A scatter plot with fitted lines showing the relationship between dapagliflozin dose (mg) on a logarithmic x-axis and CFB in 24-hour urinary glucose (g) on the y-axis. The plot compares observed glucose values and fitted dose-response lines for healthy subjects and subjects with T2DM, with distinct markers representing each group.*
FDA Label Image

Figure 8 (Figure 8)

Figure 8 (Figure 8)
A Kaplan-Meier curve comparing the percentage of patients with events over time between FARXIGA and placebo groups. The x-axis shows months from randomization (0 to 32 months), and the y-axis shows patients with events (%). The FARXIGA group has a lower event rate than placebo. Patient numbers at risk decrease over time for both groups.*
FDA Label Image

Farxiga Figure 2 (Image 01)

Farxiga Figure 2 (Image 01)
Line graph showing adjusted mean change from baseline in HbA1c (%) over 24 study weeks comparing FARXIGA 10 mg plus Metformin, FARXIGA 10 mg alone, and Metformin alone. The x-axis represents study weeks, and the y-axis represents percentage change in HbA1c. The graph includes a side plot for Week 24 using last observation carried forward (LOCF) values with 95% confidence intervals.*
FDA Label Image

Farxiga Figure 3 (Image 02)

Farxiga Figure 3 (Image 02)
A line graph comparing adjusted mean changes from baseline in HbA1c (%) over 24 study weeks between two treatments: Placebo plus Metformin and Farxiga 10 mg plus Metformin. The graph shows HbA1c reductions for both groups with Farxiga plus Metformin demonstrating a greater decrease. Error bars indicate 95% confidence intervals at week 24.*
FDA Label Image

Label Image (Lbl500903481)

Label Image (Lbl500903481)
FARXIGA 10 mg film-coated tablets label from A-S Medication Solutions. The label specifies that each tablet contains the equivalent of 10 mg dapagliflozin as dapagliflozin propanediol. Storage instructions indicate to keep the product at 68 to 77 degrees Fahrenheit. The package contains 30 tablets. Additional information includes lot number, product number, barcodes, and distributor details.*
FDA Label Image

Label Image (Lbl500903482)

Label Image (Lbl500903482)
FARXIGA 5 mg film-coated tablets label from A-S Medication Solutions. The label includes the active ingredient dapagliflozin and instructs storage at 68 to 77 degrees Fahrenheit. It specifies a package containing 30 tablets and includes the National Drug Code (NDC) 50090-3482-0 along with the product number, lot, and a barcode.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.